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Summary The endocrine and therapeutic effects of the LHRH agonist Zoladex have been assessed in 28
post-menopausal women with advanced breast cancer. Fourteen had responded to previous hormone therapy
and 14 had no previous hormone therapy. There were two partial responses and two patients with stable
disease for more than 6 months in the former group, and one partial response and two with stable disease for
more than 6 months in the latter group. Toxicity was minimal. All responses occurred in soft tissue. Six out
of seven patients who received tamoxifen after progression of disease on Zoladex showed a response.
Peripheral oestradiol levels were measured, and they fell after 1 month from 33 pmol -I (±20, s.d.) to
22pmoll-1 (±11, s.d.) (P<0.005). Responders and non-responders showed similar changes in oestradiol.
Oestrone levels did not change significantly. These results suggest that Zoladex acts indirectly via changes in
peripheral hormones, rather than directly on LHRH receptors on the tumour.
Recently luteinising hormone releasing hormone (LHRH)
agonists have been shown to have direct inhibitory effects on
human breast cancer cell lines in vitro and low affinity
binding sites were demonstrated (Miller et al., 1985;
Blankenstein et al., 1985). LHRH binding sites have also
been demonstrated in primary breast tumours (Eidne et al.,
1985). Therefore, LHRH agonists such as Zoladex
(Goserelin) have been assessed for potential efficacy in post-
menopausal breast cancer, on the assumption that a
therapeutic effect may indicate a direct antitumour effect
(Plowman et al., 1986; Waxman et al., 1985), whereas in pre-
menopausal women the major effect would be via ovarian
suppression (Nicholson et al., 1985). However, other
endocrine effects may occur in post-menopausal women.
In the post-menopausal woman, adrenal and ovarian
androgens are the main source of oestrogens (Judd et al.,
1982, 1974; Grodin et al., 1973). They are converted
peripherally by aromatase to oestrone and oestradiol.
Inhibitors of aromatase (e.g. aminoglutethimide) are effective
endocrine therapies in the treatment of post-menopausal
breast cancer (Harris et al., 1983c) and occasionally pre-
menopausal breast cancer (Bezwoda et al., 1987; Wander et
al., 1986). In the latter case, it has been suggested that
intratumour conversion of androgens to oestrogens may be
important and direct inhibition may be important, without
any detectable lowering of peripheral oestrogens (Miller et
al., 1982; Bezwoda et al., 1987).
Hydrocortisone alone can suppress adrenal androgen
production (Harris et al., 1984) and hence lower peripheral
oestrogen levels (Harris et al., 1984). We have recently
shown that the androgens produced by the post-menopausal
ovary are under pituitary FSH and LH control (Dowsett et
al., 1988). Zoladex may therefore have indirect endocrine
effects on post-menopausal breast cancer. We have evaluated
in this study the therapeutic effects of Zoladex and the
correlation of response with peripheral endocrine changes in
post-menopausal breast cancer patients.
Materials and methods
Twenty-eight post-menopausal patients with locally advanced
or progressive breast cancer were studied. Fourteen had no
previous endocrine therapy and 14 had previously shown
either stable disease for more than 6 months or partial
response to other endocrine therapies.
Twelve patients had received Tamoxifen and three had a
complete response, seven had a partial response and one
stable disease. Eight had been given aminoglutethimide and
four had a partial response. No patient had received
chemotherapy. Other pre-treatment characteristics are shown
in Table I.
Patients received monthly subcutaneous Zoladex, 3.6mg,
after infiltration of the local site with lignocaine. Response
was assessed by UICC criteria (Hayward et al., 1977). After
Zoladex failure, patients who had received no previous
endocrine therapy were treated with Tamoxifen 20mg daily
when appropriate.
Oestrone and oestradiol were measured by radio-immuno-
assays which we have previously described (Harris et al.,
1983a; Dowsett et al., 1987). These analyses have been
specifically developed for the analysis of post-menopausal
plasma oestrogen levels and have sensitivity limits of 30 and
3 pmol 1I respectively.
Results
Responses to endocrine therapy
Three patients showed partial responses for durations of 21
weeks and 141 weeks (continuing) and one patient died after
6 weeks from other causes. Four patients showed stable
disease for more than 6 months (range 29-66 weeks). All
responses were in soft tissues. Twenty-one patients had
progressive disease.
Previous hormone therapy did not affect the likelihood of
response to Zoladex. Of the 14 patients with previous
endocrine therapy, two showed partial responses and two
stable disease, while of the 14 with no previous endocrine
treatment, one showed a partial response and two stable
disease.
Toxicity was minimal, with no complaints of problems
Table I Pre-treatment characteristics
Age (years)
Time from LMP (years)
Disease-free interval (weeks)
Pre-treatment weight (kg)
Time from first relapse to
start of Zoladex (weeks)
Mean Median Range
67 70 32- 83
21 22 3- 39
103 45 0-471
62 65 42-102
73 2 0-508
Correspondence: A. L. Harris.
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Previous endocrine therapy, 14
Sites of disease: Soft tissue 23, lung 1, liver 1, nodes 9, bone 7.
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with the injection sites. Five patients had mild nausea in the
first few days after the initial Zoladex injection and one
patient complained of increased post-menopausal flushes.
Median survival from first recurrence was 305 weeks (log
rank analysis). Median survival from start of Zoladex was
140 weeks (log rank analysis).
Response to Tamoxifen after Zoladex
Suitable patients who had not received prior hormone
therapy were given Tamoxifen once disease progressed on
Zoladex. Seven patients were thus treated and two with
stable disease on Zoladex had a partial response to
Tamoxifen. Of five with progressive disease on Zoladex, one
had a complete response, two had a partial response (14
months and 7 months continuing) and one had stable disease
(14 months continuing) on Tamoxifen.
Endocrine changes on Zoladex and response to therapy
Oestradiol levels were significantly suppressed 1 month after
starting therapy (paired t test, P<0.005), but there was no
significant depression of oestrone levels (Figure 1). Although
average levels of oestrone fell, there was a wide variation
overall.
The pre-treatment oestrone and oestradiol levels and post-
treatment values did not differ between the responders
(including those with stable disease) and non-responders
(Table II). The patient with the best response did show the
greatest suppression of oestradiol levels (43 to 13pM, 71%
reduction), which was maintained on therapy. Her oestrone
levels were not suppressed.
Hormones were measured monthly in all patients.
Oestradiol suppression was maintained and there was no
evidence of hormone 'escape'.
Discussion
This study shows that objective responses to an LHRH
agonist can be obtained in post-menopausal breast cancer.
Objective responses have been reported by Plowman et al.
(1986) in two of ten previously untreated patients. Waxman
et al. (1985) in a phase 2 study of another LHRH agonist
found one minor response in 18 and that was in a previously
untreated patient. In our study there were similar responses
in the previously treated patients, although they were
selected for previous response to other endocrine therapies.
Tamoxifen subsequently produced responses in six of
seven patients in the group treated with Zoladex as initial
therapy. These patients had favourable characteristics for
response, i.e. soft tissue disease, few sites of disease and post-
menopausal status. The low response rate to Zoladex is
therefore unlikely to be due to intrinsic resistance to steroid
hormone therapy, and the high response to Tamoxifen
would be expected based on our selection criteria.
Other series report endocrine data as showing no
significant changes in oestradiol or oestrone. However,
details of the sensitivity of the assays were not presented in
one study (Plowman et al., 1986) and in the other the lower
limit of detection of oestradiol was 50pmoll-1 (Waxman et
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Figure 1 Effects of Zoladex on oestradiol and oestrone levels.
Hormone levels were measured before therapy and 1 month later
(*P<0.005). Bars represent s.e.m., n =25 paired observations.
E1, oestrone; E2, oestradiol.
al., 1985). Clearly, this would fail to detect any significant
change, since in our series the mean pre-treatment value was
33 pmol1- . Our series is larger than previously reported
studies and small changes in oestradiol may not have been
detected on lesser numbers of patients.
The study was carried out to test the hypothesis that
LHRH agonists may have direct antitumour effects. The
levels of Zoladex achieved in vivo are in the range 1-4nM
(Clayton et al., 1985). Another LHRH agonist, Buserelin,
inhibits the growth of the human breast cancer cell line
MCF7 at concentrations of 1 nM or greater (Miller et al.,
1985; Foekens et al., 1986). However, the affinity of the
receptors is much lower than this - approximately 1 tiM.
Results with Zoladex in vitro have not been reported.
We have recently shown that the post-menopausal ovary is
still stimulated by FSH and LH to produce androgens, and
suppression of FSH and LH with Zoladex reduced
androstenedione and testosterone plasma levels (Dowsett et
al., 1988). Since these steroids are precursors of oestrogens,
the latter were also decreased. The suppression of oestradiol
is more marked than that of oestrone and this may be due to
the greater suppression of testosterone rather than
androstenedione (Dowsett et al., 1988), which are the
respective precursors of the oestrogens.
Because of the peripheral endocrine effects, it is probable
that the reductions in peripheral oestrogens are contributing
to the therapeutic effect and the small reduction accounts for
the low response rate compared to anti-oestrogens. It is
interesting to note that the patient with the best response of
longest duration showed the greatest fall in oestradiol levels.
There was no general correlation of hormone suppression
with response, and this has been noted for other hormone
suppressive therapies (Santen et al., 1982; Harris et al.,
1983b).
This study does not exclude LHRH receptors as a target
for Zoladex, but we think that the suppression of oestradiol
is a more likely explanation of the low response rate,
whereas 20 of 30 patients reported by Eidne et al. (1985) had
LHRH receptors in their tumours.
Because of its effect on suppression of ovarian androgens,
Table II Oestrone and oestradiol levels in responders and non-responders
Oestrone(EI) Oestradiol(E2)
Pre Post Mean % Pre Post Mean %
(pmoll1) (pmoll1) fall (pmol l 1) (pmol l 1) fall
Responders Mean 142 111 4 33 22 10
s.d. 88 36 67 21 10 50
Non-responders Mean 125 110 4 30 22 16
s.d. 59 57 69 17 11 33ZOLADEX AND POST-MENOPAUSAL BREAST CANCER 9
Zoladex should be further evaluated in combined endocrine
therapy, since it may contribute to depletion of androgens
that could be an intratumoral substrate for oestrogen
production, as well as lowering peripheral oestradiol levels.
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